Best Life Sciences Companies in Suwon-si, South Korea
The 40 best Life Sciences companies in Suwon-si, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: IMBiologics.
Our analysis of 50 Life Sciences companies
$4.0b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Suwon-si
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IMBiologics Developer of antibody therapeutics to treat cancer and autoimmune diseases 40Moat top 32%Funding top 33%Patents top 36%Innovation top 45% All 6 signals ▾Moattop 32% Fundingtop 33% Patentstop 36% Innovationtop 45% Marketbottom 41% Globalbottom 40% Moat: Editorial + unicorn rating 4/10 · IP moat: 23 patents Funding: Raised $33.8M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $34M | 37 mo ago | Public | — | 2020 | — | 23 patents Engineered antibody/fusion protein therapeutics with half-life extension and bispecific immune targeting | — |
| 2 | Advanced Protein Technologies Developer of biomaterials based on recombinant protein production technology | $17M | 57 mo ago | Series B | Chul Shin CEO | 2001 | — | 65 patents Production and therapeutic use of 2'-fucosyllactose oligosaccharides in nutrition and medicine | — |
| 3 | Centenaire Biosciences Developer of antibody therapies to treat cancer and immune diseases | $16M | 53 mo ago | Series A | Yang Cheol CEO | 2017 | ZURB FoundationNginxCloudflare+23 | 14 patents Engineered antibodies with dual Fc domains for improved therapeutic half-life and effector function | 2 launchs · 1 partnership |
| 4 | MedPacto Company developing ALK-5 kinase inhibitors for treating solid tumors and multiple myeloma | $16M | 68 mo ago | Public | — | 2013 | PHPGSAPNginx+6 | 107 patents Targeted antibody therapeutics/diagnostics for oncology and arsenic-based metabolic liver disease treatments | — |
| 5 | MBD Biotech Provider of drug efficacy and toxicity testing services | $10M | — | Series B | Bo Ku CEO | 2015 | — | — | — |
| 6 | AbTis Provider of technology for antibody-drug conjugation | $4M | 98 mo ago | Seed | Sang Jeon Chung Founder & CEO | 2016 | — | 65 patents Site-specific antibody‑drug conjugates and Fc‑binding linker technologies for targeted therapeutics | — |
| 7 | Kalos Medical Developer of medical devices for the treatment of hypertension & other chronic diseases | $4M | 38 mo ago | Funding Raised | Chul Kim CEO | 2015 | — | 35 patents Catheter-based minimally invasive nerve denervation and block devices for medical procedures. | — |
| 8 | Mimetics Developer of skin and tissue adhesive patch | — | 29 mo ago | Seed | Park Ki CEO | 2023 | WordPressMySQLPHP+14 | 24 patents Transdermal negative-pressure adhesive patches and stem‑cell based anti‑aging cosmetic formulations. | — |
Top 11 Life Sciences companies in Suwon-si
#1
Public · Suwon-si, Gyeonggi-do · founded 2020 · 25 employees$33.8Mraised▾
Developer of antibody therapeutics to treat cancer and autoimmune diseases. The company has developed a platform technology called ePendy that can generate antibody therapeutics for the treatment of autoimmune diseases and cancer.
- Jul 2023Series B$15.5M
- Aug 2021Series A$14.7M
- Jan 2021Seed$3.6M
#2
Funding Raised · Suwon-si, Gyeonggi-do · founded 2015$3.5Mraised▾
Developer of medical devices for the treatment of hypertension & other chronic diseases. The company uses a proprietary catheter-based technology to develop DENEX, a medical device for the treatment of hypertension for renal denervation.
- Jul 2023Grant (prize money)$3.5M
#3
Series A · Suwon-si, Gyeonggi-do · founded 2021$16.4Mraised▾
Developer of antibody therapies to treat cancer and immune diseases. The company focuses on developing an antibody platform based on proprietary technology to develop cancer-targeted drugs. The flagship product of the company is CTN001 a human epidermal growth factor receptor 2 (HER2)-targeting antibody, to treat HER2-low-expressing breast cancer.
- Mar 2022Series A$16.4M
#4
Series B · Suwon-si, Gyeonggi-do · founded 2001 · 11 employees$17.3Mraised▾
Developer of biomaterials based on recombinant protein production technology. The platform is manufacturing and developing protein products that can be used for medicine, food, and the cosmetic industry. The platform has developed the proprietary technology rProtein Manufacturing AD-Pure System for the production of recombinant protein.
- Nov 2021Series B$17.3M
- 2018Seed—
#5
Public · Suwon-si, Gyeonggi-do · founded 2013 · 62 employees$16Mraised▾
MedPacto, spun-off from Theragen Etex, (a specialized genomics company) is engaged in the development of small molecules for cancer. Their lead candidate which is currently undergoing Phase 1 trials is TEW-7197, an inhibitor of ALK-5 to block signal transduction by TGF-b and TEW-0201, an inhibitor of BRAF and c-RAF, which is in the preclinical stage. TEW-7197 was originally developed by the Ewha Woman's University with government support of the Program for Disease-Based Discovery of Global New Drug Candidates and was out-licensed from Ewha to MedPacto.
- Dec 2020Post IPO$90.2M
- 2018Series A$16M
#6
Series B · Suwon-si, Gyeonggi-do · founded 2015 · 30 employees$10.2Mraised▾
mbdbiotech has developed a chip structure of pillar/well called Cellvitro for the testing of efficacy and toxicity. The company has also developed the dispensor and scanning machines(ASFA™) for 3D cell culture based on hydrogel encapsulation to predict the interaction or the reactivity of drugs in human body through .
- Series B$10.2M
#7
Seed · Suwon-si, Gyeonggi-do · founded 2016 · 24 employees$4.5Mraised▾
Abtis provides the technology for antibody-drug conjugation. It offers its proprietary technology AbTis linker for site-specific binding and AbTis Michelle for drug solubility. Its pipeline product also includes mAbs drug conjugates.
- Jun 2018Seed$4.5M
#8
Seed · Suwon-si, Gyeonggi-do · founded 2023—raised▾
Developer of skin and tissue adhesive patch. The company is developing skin patch to enhance adhesion technology across a broad range of industries from skin-safe pharmaceutical delivery and human tissue adhesion to skin-mounted sensors.
- Mar 2024Seed—
#9
Seed · Suwon-si, Gyeonggi-do · founded 2017 · 9 employees—raised▾
Provider of therapeutics solution for cancer, glaucoma, and other diseases. The company flagship product NXT-301, prevent the hyper-methylation in mature cells, and NXT-101 target the IOP (intraocular pressure), cGMP (cyclic glucoside monophosphate), and sGC (soluble guanylate cyclase) for treating diabetes.
- Apr 2023Seed—
#10
Seed · Suwon-si, Gyeonggi-do · founded 2017—raised▾
Provider of big data analytics and AI-driven platforms for healthcare and drug discovery. It provides tools like 3X-TMiner for literature mining, 3X-KBank for knowledge banking, and AI/ML solutions for genomics, proteomics, drug repositioning, and metagenome analysis.
- Jan 2023Seed—
#11
Public · Suwon-si, Gyeonggi-do · founded 2001 · 175 employees—raised▾
Provider of point-of-care diagnostics for multiple diseases. It offers technology for POC molecular diagnostics, fluorescent immunoassay, immunochromatography, BGMS and CGMS. The products include SD A1care is an immunochromatographic analyzer for HbA1c levels in blood, SD Lipidocare for monitoring blood cholesterol levels, and SD GlucoNavii is for rapid glucose measurement.
- 2020Post IPO—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in South Korea
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 885 South Korea-affiliated papers.
- Ministry of Agriculture118
- Ministry of Education70
- Seoul National University53
- Yonsei University44
- Korea University36
- Gene2→26
- Genome1→10
- Transcription factor1→9
- Genome editing1→6
- Transformation (genetics)1→6
- Antimicrobial1→23
- Apoptosis1→12
- Cell culture2→10
- Cytotoxicity2→8
- Gene knockdown1→7
- Human health2→11
- Health benefits1→6
- Antibiotic resistance1→4
- Toxicity2→4
Where biotechnology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in South Korea
South Korea biotechnology patent filing is accelerating — 58,964 filings from 8,000 assignees (2016–2025), led by CJ Cheiljedang, UNIV Korea RES & BUS Found, Samsung; annual filings 4052→6791.
- CJ Cheiljedang6608
- UNIV Korea RES & BUS Found1920
- Samsung1764
- Korea Advanced INST SCI & TECH1756
- Seoul NAT UNIV R&DB Foundation1752
- Korea RES INST Of Bioscience1535
- Hanmi Pharm IND1198
- Korea RES INST Bioscience & Biot1009
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.